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Background: In 2010, an Iberian ibex (Capra pyrenaica hispanica) stock reservoir was established for conservation
purposes in north-eastern Spain. Eighteen ibexes were captured in the wild and housed in a 17 hectare enclosure.
Once in captivity, a caseous lymphadenitis (CLA) outbreak occurred and ibex handlings were carried out at six-month
intervals between 2010 and 2013 to perform health examinations and sampling. Treatment with a bacterin-based
autovaccine and penicillin G benzatine was added during the third and subsequent handlings, when infection by
Corynebacterium pseudotuberculosis was confirmed. Changes in lesion score, serum anti-C. pseudotuberculosis
antibodies and haematological parameters were analyzed to assess captivity effects, disease emergence and
treatment efficacy. Serum acute phase proteins (APP) Haptoglobin (Hp), Amyloid A (SAA) and Acid Soluble
Glycoprotein (ASG) concentrations were also determined to evaluate their usefulness as indicators of clinical
status.
Once in captivity, 12 out of 14 ibexes (85.7%) seroconverted, preceding the emergence of clinical signs;
moreover, TP, WBC, eosinophil and platelet cell counts increased while monocyte and basophil cell counts
decreased. After treatment, casualties and fistulas disappeared and both packed cell volume (PCV) and
haemoglobin concentration significantly increased. Hp, SAA and ASG values were under the limit of detection
or showed no significant differences.
Conclusions: A role for captivity in contagion rate is suggested by the increase in antibody levels against
C. pseudotuberculosis and the emergence of clinical signs. Although boosted by captivity, this is the first report of an
outbreak of caseous lymphadenitis displaying high morbidity and mortality in wild ungulates. Treatment consisting
of both vaccination and antibiotic therapy seemed to prevent mortality and alleviate disease severity, but was not
reflected in the humoural response. Haematology and APP were not useful indicators in our study, perhaps due to
the sampling frequency. Presumably endemic and irrelevant in the wild, this common disease of domestic small
ruminants is complicating conservation efforts for the Iberian ibex in north-eastern Spain.
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Corynebacterium pseudotuberculosis causes widespread
abscesses in the lymph nodes, subcutaneous tissues and
internal organs of buffaloes, wild ruminants, camels, cat-
tle and horses [1-3]. It is the causative agent of caseous
lymphadenitis (CLA), a disease occurring worldwide that
primarily affects domestic small ruminants [4]. In wild-
life, C. pseudotuberculosis has been previously described
as isolated cases in pronghorns (Antilocapra americana)
[5], elk (Cervus elaphus canadensis) [6] and Arabian
oryx (Oryx leucoryx) [7], or as chance findings during
routine meat inspection of antelope carcasses from a
South African game reserve [8]. Human infection is also
possible but unusual, being mostly related to occupa-
tional exposure [9]. C. pseudotuberculosis infection oc-
curs through the oral, nasal and ocular mucosa, or
through skin wounds. The bacterium can survive up to
eight months in faeces, fomites or in the soil, a fact that
favours its maintenance in small ruminant flocks world-
wide. The principal clinical sign of CLA in sheep and
goat is lymph node abscessation, which may be closed or
fistulised, discharging pus and contaminating the envir-
onment. Infected animals without clinical signs also can
shed bacteria through their respiratory tract and mech-
anical vectors such as flies have also been described to
play a role [1,10].
Economic losses due to CLA are an important issue in
the sheep and goat industries because of the reduction
in wool, meat and milk production, the decrease of
reproductive rates and the losses due to condemnation
of carcasses and skins in abattoirs [1,10]. Lamentably,
classical serological tests show inadequate sensitivity or
specificity to detect contact with C. pseudotuberculosis
[1], making disease detection difficult. Nevertheless, some
enzyme-linked immunoabsorbent assay (ELISA) diagnostic
tests have been observed to be effective in control and
eradication programs, especially those based on phospho-
lipase D (PLD) as an antigen [11,12]. Recently developed
ELISA tests based on the detection of gamma interferon
(IFN-γ) appear to be more sensitive in detecting early
infection [12,13].
Disease management in sheep flocks is based on lan-
cing and flushing-out or the surgical removal of lesions
accompanied by topical disinfection and parenteral anti-
biotic treatment for 4? 6 weeks [4,10]. Special care must
be taken to prevent environmental contamination during
drainage of the abscesses [10]. The effectiveness of such
management measures strongly relies on the close sur-
veillance of new infections, which is very difficult due
the above-mentioned limitations in disease diagnosis.
Vaccination has been the main strategy for CLA control
in countries where the disease is endemic. Several vac-
cines have been developed and used with varied out-
comes. The earliest ones consisted of bacterin-basedvaccines, which initially displayed limited efficacy [14]
but have improved over time [15,16]. The ability of PLD
to protect against CLA encouraged toxoid vaccine stud-
ies [17], and combined bacterin-toxoid vaccines have
also been used with success [18]. Live vaccines also elicit
strong humoural and cell-mediated immune responses
in goats and sheep [1,19]. Finally, the use of autogenous
vaccines has been supported both in the literature and
by veterinary practitioners for the treatment of CLA at
herd level [20].
The Iberian ibex (Capra pyrenaica) is an endemic wild
ruminant of the Iberian Peninsula, whose range is
expanding both in Spain and Portugal [21-23]. The Red
List of Threatened Species of the International Union
for Conservation of Nature (IUCN) considers the status
of C. pyrenaica hispanica to be of Least Concern (LC)
[23]. However, threats such as fragmentation, competi-
tion with domestic livestock and other introduced wild
ungulates or illegal hunting occur [24]. In addition, dis-
eases have been one of the main factors responsible for
demographic changes in the recent history of this spe-
cies. The impact of sarcoptic mange, caused by Sarcoptes
scabei, has been of particular relevance, causing mortal-
ities of over 95% in ibex populations in southern Spain
[25]. Other pathogens, such as Mycoplasma agalactiae,
have caused less severe outbreaks in some Iberian ibex
populations [26]. This is both a conservation issue and
an economic concern in those regions where game ex-
ploitation (trophy hunting) of this valuable species oc-
curs [27]. Hence, because of the biological value of this
species and the ever present risk of game cessation due
to disease outbreaks, the creation of stock reservoirs of
Iberian ibexes have been promoted by the environmental
agencies of the Spanish government in the main areas of
distribution of this species (i.e., Sierra Nevada, Sierra de
Cazorla and Serran?a de Cuenca Natural Parks in southern
and central Spain, respectively). In 2010, the threatening
south? north advance of sarcoptic mange in the Iberian
Peninsula prompted the decision to create a new stock res-
ervoir of Iberian ibexes in the, up to date, sarcoptic mange-
free subpopulation of the National Game Reserve of the
Ports de Tortosa i Beseit (NGRPTB). This study analyzes
the role of captivity in the development of a CLA outbreak
that occurred in this new captive population and evaluates
the effect of a CLA vaccine-based treatment on the occur-
rence of clinical signs, the immune humoural response,
changes in haematological parameters, and acute phase
protein (APP) concentrations.
Materials and methods
Study area and period
The study area is situated in the NGRPTB (40?48 ? 28 ? N,
0?19 ? 17? E), in Catalonia, north-eastern Spain. Specifically,
this study was carried out in an enclosure of 17 hectares
Table 1 Result of the clinical examination performed in
every ibex (ID) at each handling time (t0-t5) expressed as
lesion status: FL: Presence of fistulas; GLS: generalized
lymph node swelling; LLS: Local lymph node swelling;
NL: No apparent affectation; ND: No data
ID t0 t1 t2 t3 t4 t5
1 NL Died during transport
2 NL Died into enclosure
3 NL Escaped from enclosure
4 NL
5 NL NL Euthanatized into the enclosure
6 NL FL
7 NL FL NL NL NL NL
8 NL GLS NL NL NL NL
9 NL GLS NL NL NL NL
10 NL GLS GLS LLS NL NL
11 NL LLS LLS LLS NL NL
12 NL LLS LLS NL NL NL
13 NL LLS GLS LLS NL NL
14 NL ND FL GLS NL NL
15 NL ND LLS LLS NL NL
16 NL LLS LLS LLS NL NL
17 NL ND FL GLS LLS ND
18 NL GLS ND LLS NL NL
19 New born NL LLS LLS LLS GLS
20 LLS LLS LLS NL ND
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of Iberian ibex. The facilities consist of a double periph-
eral fence, to prevent contact with animals outside of
the fence, a quarantine area, a warehouse and a smaller
fenced area with troughs and connected to a capture
corral trap. The study was carried out between March
2010 and January 2013.
Animals and samples
The founding ibex population
Eighteen ibexes were captured in 2010 (t0) by means of
seven fixed box-traps scattered throughout the NGRPTB.
Once trapped, the ibexes were darted by means of a blow-
pipe and anaesthetized with a combination of xylazine
(3 mg/kg; Xilagesic? 20%, 200 mg/ml, Laboratorios Calier,
Barcelona, Spain) and ketamine (3 mg/kg; Imalgene? 1000,
100 mg/ml, Merial, Lyon, France) [28]. One ibex died
during transport from the box-trap site to the enclos-
ure. Another ibex died once in captivity (between t0 and
t1) and two escaped from the enclosure before the first
handling (t1). On the other hand, two newborn ibexes
from females captured pregnant in the wild added to the
founding population within the enclosure between t0 and
t1. Hence, sixteen ibexes, ten females and six males aged
one to eleven years, were used for our longitudinal stud-
ies. Two of these ibexes were euthanized between t1 and
t2 due to draining fistulas and in order to prevent disease
spread. See Table 1 to ease understanding. All the death
and euthanized ibexes were necropsied. Age of adult
ibexes captured in the wild was determined by horn seg-
ment counts [29]. Individual identification was done by
means of both ear tags and subcutaneous passive inject-
able transponders of 32 ? 3.8-mm placed in the axillary
area (Model Ri-Trp-RC2B, Tiris, Texas Instruments,
Almelo, The Netherlands).
Management of the CLA-infected ibex stock reservoir
Routine handlings began in June 2011 (t1) and were
initially planned once a year. Nevertheless, owing to the
CLA outbreak and the commencement of treatment, the
second and third handlings took place in December
2011 (t2) and January 2012 (t3), respectively, and contin-
ued at six month intervals until January 2013 (t5). See
the detailed chronology in Figure 1. To carry out han-
dlings, the ibexes were captured, physically restrained,
blindfolded, and held in 4x4 cm mesh sack nets (Ziboni
Ornitecnica?, Bergamo, Italy). The ibexes were then con-
centrated in a handling zone and treated with aceproma-
zine maleate (0.1 mg/kg; Calmo Neosan?, 5 mg/ml,,
SmithKline Beecham, Madrid, Spain) to alleviate capture
stress [30]. The handling protocol included collection
of blood, administration of ivermectin (0.2 mg/kg sc;
Ivomec? 1%; Merial, Toulouse, France), checking of ear
tags and microchips and an external clinical examination.After CLA emergence, ibexes were also vaccinated and
treated with penicillin G benzatine (1.2 million IU, intra-
muscular; Benzatard?; Syva, Le?n, Spain) in each hand-
ling. Blood samples were collected from the jugular vein
with disposable 10 ml syringes fitted with 0.8 ? 25 mm.
needles and processed within 12 h of collection. Two
millilitres of each sample were placed in commercial
tubes with tripotassium ethylenediaminetetraacetic acid
(EDTA K3) as an anticoagulant. The remaining volume
was placed in tubes for serum collection, allowed to
clot at room temperature and centrifuged at 1800 g.
Serum was frozen at −20?C until testing. The purpose
of clinical examination was mainly to evaluate lymph
node swelling (size and texture) and included palpation
and visual inspection of the superficial lymph nodes of
the head, neck, shoulders and hind limbs. To reduce
variability and subjectivity, all examinations were done
by the same person (GM, veterinary). Four clinical cat-
egories were established in order to perform the lesion
score: ibexes with no apparent lesions (NL), local lymph
node swelling (LLS), generalized lymph node swelling
(GLS) and ibexes with the presence of fistulised lymph
nodes (FL).
Figure 1 Diagram of the handlings dates with the corresponding treatment and location of the ibexes at each handling time.
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Bacteriology
Selected samples were collected from the four necrop-
sied ibexes and from a fifth live ibex that healed after
swabbing when presenting with a fistula during the t2
handling. Samples were directly cultured on blood agar
base supplemented with 5% sterile defibrinated sheep
blood (Oxoid S.A., Spain). Colonies obtained after 24 ?
48 h of aerobic incubation at 37?C were Gram-stained.
Colonies of bacteria with morphological characteristics
compatible with C. pseudotuberculosis were tested using
API Coryne Strip (API CS; bioM?rieux, France) accord-
ing to the manufacturer ? s recommendations. The API
CS method involves a battery of 20 tests and the results
are interpreted using the API web system (see: https://
apiweb.biomerieux.com/servlet.)
Serologic analyses
An indirect ELISA to detect C. pseudotuberculosis anti-
bodies was performed according to Solanet et al. [31].
Two different stumps were used to acquire the antigens;
one from CLA-infected farm goats from the Region of
Murcia, south-eastern Spain, and the other from the
CLA-infected ibexes. Six sera from domestic goats of
farms free of paratuberculosis, tuberculosis and pseudo-
tuberculosis in the Region of Murcia (Spain) were used
as negative controls. Five serum samples from CLA clin-
ical cases confirmed by histopathological and bacterio-
logical analyses in domestic goats from the Region of
Murcia were used as positive controls. Optical density
(OD) was corrected by blank well lecture, and the cut-
off values were calculated as the mean of negative sera
OD (blank corrected) + 3 S.D. Another ELISA was done
to detect antibodies against Mycobacterium bovis [32]
using as the antigen the recombinant protein MPB70
from Mycobacterium bovis provided by Jim McNair
(Belfast, Northern Ireland, United Kingdom). A cut-off
value was calculated using ten sera obtained from ten goats
in a tuberculosis-free herd (Experimental Farm, School of
the Veterinary Medicine, Murcia). These negative control
animals previously tested negative for tuberculosis by skin
test and the IFN-γ release assay.
Finally, a commercial ELISA kit was used to detect
antibodies against Mycobacterium avium subsp. para-
tuberculosis -MAP- (Parachek?, Prionics AG, Zurich,Switzerland). Results were expressed as OD after reading
the plates at 450 (C. pseudotuberculosis) or 405 (M. bovis
and MAP) nm in an ELISA plate reader (DigiScan with
DigiWin Software, ASYS Hitech, Austria).
Haematology
The erythrocyte (RBC), leukocyte (WBC), platelet (PLT)
and differential WBC (lymphocytes [Lymph], neutrophil
[Neut], eosinophil [Eos], monocyte [Mono] and basophil
[Baso]) counts, and the haemoglobin concentration (Hb)
were determined by means of an automated laser analyzer
(Advia 120?, Bayer, Fernwald, Germany). The packed cell
volume (PCV) was measured using a microPCV centri-
fuge (Hematospin 1400, Hawksley, Lancing, England) at
14000 g for 6 min. The total protein concentration (TP)
was determined by refractometry (Euromex RD 712 clinical
refractometer; Euromex, Arnhem, Netherlands).
Acute phase protein
Serum concentration of haptoglobin (Hp) was quantified
using a commercial spectrophotometric assay (Phase
Haptoglobin assay, Tridelta Development Ltd, Ireland).
Serum amyloid A (SAA) concentration was determined
with a commercial solid phase sandwich ELISA (Phase
SAA assay, Tridelta Development Ltd, Ireland). Analyses
were performed according to the manufacturer ? s instruc-
tions and the final absorbance measured in a microtitre
plate reader (PowerWave XS, Bio-Tek Instruments Inc.,
Vermont, USA) at 630 nm and 450 nm for Hp and SAA,
respectively. These analytical determinations were recently
validated [33].
Acid soluble glycoprotein (ASG) concentration was
also quantified as it correlates well with alpha-1-acid
glycoprotein (AGP) in most species [34]. The ASG com-
ponent of the serum samples was determined using the
method described in Winzler (1955) [35], modified by
Nagahata et al. [36] and Eckersall et al. [34], and opti-
mized by Tecles et al. [37]. Briefly, serum was precipitated
by mixing with perchloric acid and then centrifuged at
1750 g for 10 min. Next, 20 μl of supernatant was mixed
with 196 μl of the reagent bicinchoninic acid (Sigma
chemical Company, St. Louis, Missouri, USA), the mixture
incubated at 37?C for 25 s, and then 4 μl of copper
sulphate (Sigma) added as a start reagent. The protein
content in the supernatant was then measured after
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France) at a wavelength of 550 nm. Commercial purified
bovine α1-acid glycoprotein (AGP; Sigma) was used as a
standard. A stock solution was prepared by diluting 25 mg
of bovine AGP in 5 ml of distilled water and a standard
curve performed by mixing the stock solution with per-
chloric acid at a 1:4 dilution.
Therapeutic intervention
An autovaccine containing 1 ? 10 8 cfu/ml of the C. pseu-
dotuberculosis isolated from the CLA-infected ibexes,
and a strain of Archanobacterium haemolyticum previ-
ously isolated at the Department of Animal Health at the
University of C?rdoba, which presents strong immuno-
genic properties against other corynebacterial species,
was elaborated (unpublished data). Briefly, C. pseudotu-
berculosis and A. haemolyticum isolates were cultivated
in brain heart infusion (Oxoid, Spain) at 37?C for 24 h
and inactivated with 0.3% formaldehyde (30-40% w/v,
Panreac, Spain). The suspension was centrifuged at 720 g
for 15 min at 4?C and the pellets re-suspended in an iso-
tonic saline solution until the pattern 0.5 in the McFarland
scale was obtained. The vaccination scheme consisted of
5 ml subcutaneous (sc) doses (2 ml for juveniles), with the
first dose on December 2011 (t2) followed by revaccin-
ation one month later (t3) and subsequent doses
every 6 m, on July 2012 and January 2013 (t4 and t5,
respectively). Penicillin G benzatine (1.2 million IU, intra-
muscular; Benzatard?; Syva, Le?n, Spain) was administered
to reduce infection progression. Penicillin G has demon-
strated high action against Corynebacterium spp. in anti-
biograms (Personal communication).
Statistical analysis
Changes in the physiological responses (i.e., changes in
haematologic parameters and APP concentration) and in
anti-C. pseudotuberculosis antibody levels (i.e., Optical
Density obtained by means of ELISA) of ibexes were
assessed by means of a multivariate analysis of variance
(MANOVA). In our case, the physiological response was
defined as a canonical derived response variable named
haematologic parameters (RBC, WBC, PLT, WBC, Lymph,
Neut, Eos, Mono, Baso, Hb), APP (Hp, SAA, AGP), and
anti-C. pseudotuberculosis antibodies (O.D. CLA-ELISA)
and the explanatory factors were the handling times (from
t0 to t5). We performed three different analyses: the first
aimed to assess the early captivity effect by comparing the
anti-C. pseudotuberculosis antibody levels, and the haema-
tology and APP values between t0 and t1; the second
assessed the long-term captivity effect by comparing t0
with t1-t5; finally, for the assessment of the treatment
effect, t2 (when the treatment started) was compared with
t3 (one month later). Prior to any analysis, MANOVA as-
sumptions (i.e., correlation between dependent variables,multivariate normality and absence of residual patterns),
[38] were checked. All statistical analyses were carried out




The ibex that died during transport, the one that died
in the enclosure and the two euthanized ibexes were
necropsied and diagnosed with CLA on the basis of
multiple abscesses and a positive C. pseudotuberculosis
culture. Two additional free-living wild ibexes were diag-
nosed with CLA in 2005 and 2007 in the NGRPTB. All
affected animals (four males, 3 to 15 years old and two
females, 7 and 10 years old) had low body weights and
widespread serous fat atrophy. The most frequently af-
fected peripheral lymph nodes were those of the head
(submandibular, 2/6) and neck (prescapular, 3/6). Amongst
these six cases, four presented with internal dissemination
of the infection with lesions seen in mediastinal lymph
nodes and lungs (4/6) as well as in mesenteric lymph nodes
(3/4), kidney (2/4), spleen (1/4) and liver (1/4).
Analysis of lesions score
Results are presented in Tables 1 and 2. Clinical signs of
CLA were not detected at t0, with pathological changes
appearing between t1 and t5. Nine ibexes displayed
either localized (n = 5) or generalized (n = 4) lymph node
swelling at t1. Disease signs decreased after treatment,
when no more fistulas were observed and only three
ibexes displayed generalized infection. Finally, whereas
generalized infection and fistulas were mostly associated
with a positive CLA serological status, local and no ap-
parent lesions were indifferently associated with a CLA
positive or negative status. However, 22 out of the 24
(92%) clinical examinations where a NL status was asso-
ciated with a positive CLA serological result belonged to
individuals displaying clinical signs in previous examina-
tions. On the other hand, at least three out of the 13
clinical examinations (23%) where a LLS status was asso-
ciated with a negative CLA serological result belonged
to ibexes seroconverting and/or displaying a GLS status
later.
Laboratory results
At least 12 out of 14 ibexes (85.7%) changed their sero-
logical status once within the enclosure, as shown by the
significantly higher mean optical density in the CLA-
ELISA from t1 to t5 (Table 3). The antibody levels did
not show significant differences once in captivity (t1-t5)
(Figure 2). Three ibexes did not seroconvert during the
study period whereas one ibex displayed a positive
ELISA result in t0. Two of the ibexes that seroconverted
within the enclosure changed their serological status
Table 2 Lesions score: Number of clinical examinations performed in every handling divided by four lesion status:
FL: Presence of fistulas; GLS: generalized lymph node swelling; LLS: Local lymph node swelling; NL: No apparent
affectation; ND: No data
Ibexes FL GLS LLS NL ND
t0 18 0 0 0 18 0
t1 16 2 4 5 2 3
t2 14 2 2 6 3 1
t3 14 0 2 8 4 0
t4 14 0 0 2 12 0
t5 14 0 1 0 11 2
Period Wild (t0) 18 0 0 0 18(100%)
Captivity (t1-t5) 16 4(6.5%) 9(14%) 21(34%) 32(52%)
Treatment Before (t1-t2) 16 4(18%) 6(27%) 11(50%) 5(23%)
After (t3-t5) 14 0 3(7.5%) 10(25%) 27(67.5%)
CLA-ELISA Negative 20 0 2(22.2%) 13(61.9%) 26(52%)
Positive 4(100%) 7(77.8%) 8(38.1%) 24(48%)
These clinical examinations are put into groups to show the number of ibexes observed with every lesion status and the percentage they represent (in brackets)
before (t0) and once in captivity (t1, t2, t3, t4, t5), before (t1 and t2) and after introducing treatment (t3, t4, t5) and in relation to the CLA-ELISA results. The number of ibexes
present in every handling or included in every group is shown (Ibexes).
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the M. bovis ELISA, only one ibex displayed a tem-
porary positive result in t3 and, in the MAP ELISA,
none of the ibexes displayed antibodies against M. a.
subsp. paratuberculosis.
TP, WBC, eosinophil and platelet cell counts increased
(between one- and two-fold) whereas monocyte and
basophil cell counts decreased (three-fold) from t0 to t1
(Figure 3). Both PCV and haemoglobin concentrations
significantly increased (one-fold) from t2 to t3 (Figure 4).
Table 3 illustrates the influence of both captivity and
treatment in the physiological responses of ibexes.
All SAA values and most Hp values were under the
limit of detection considered acceptable for interpret-
ation. Only three samples displayed interpretable Hp
values, which showed no significant correlation with any
other variable. ASG values showed no significant differ-
ences according to time or lesions score or correlation
with other parameters.
Discussion
This is the first outbreak of CLA reported in Iberian ibex
and, to our knowledge, in any other wild ungulate popu-
lation. However, the infection rate leading to this out-
break of disease was favoured by captivity, as evidenced
by the increase of the antibody levels against C. pseudo-
tuberculosis, casualties and casuistry of lesions. Stress-
induced immunosuppression caused by captivity may
have favoured disease severity. The treatment including
both antibiotics and vaccination apparently prevented cas-
ualties and fistulas but was not reflected in the humoural
immune response. The ibex displaying a positive status forantibodies against C. pseudotuberculosis at t0, when first
captured in the wild, may have acted as a source of infec-
tion within the enclosure. In fact, this ibex was found dead
seven months after being placed in captivity and CLA was
diagnosed as the cause of death. Other ibexes with sub-
clinical affectation could have gone unnoticed in the
clinical exploration performed at t0. Once within the
enclosure, ibexes developing visible clinical signs such
as draining fistulas could have gone unnoticed for weeks
between handlings, contaminating the environment due to
the lack of daily on-site staff presence. Mutual grooming,
head butting, inquisitive attitudes or the habit to scratch
shoulders against hard surfaces, are typical behavioural
characters of goats that increase the risk of contagion
[4,39], and other factors may have played a role in the evo-
lution of this CLA outbreak as well. C. pseudotuberculosis
displays high levels of survival in the environment [3] and
the mechanical transmission of this bacterium by house-
flies and other Diptera has been described in cattle and
buffaloes [1,10].
Lesion score is the only evidence of a clear health im-
provement after treatment administration in the ibexes
of our study. This is also observed in other vaccine stud-
ies [40]. ELISA classified as positive some serum samples
from ibexes without clinical lesions; most of these ibexes
had suffered from the disease previously and had recov-
ered. The two individuals where this condition was not
confirmed could either have gone unnoticed between han-
dlings, suffered a subclinical affectation or could have been
false positive results. Hence, whenever available, the med-
ical record is important to interpret the ELISA results. In
addition, the clinical external examination performed in
Figure 2 Box plot showing significant differences (p = 0.001**)
between the mean optical density of the ibex CLA-ELISA
processed samples at the moment of first capture in the wild (t0)
and in the subsequent handlings (t1, t2, t3, t4, t5).
Table 3 MANOVA and specific ANOVA showing influence
of Iberian ibex captivity (t0 ibexes were in the wild, t1-t5
in the enclosure), and treatment (t2 and t3, before and
after treatment, respectively) on physiological parameters
(i.e., haematological parameters and acute phase protein
concentration) and anti-C.pseudotuberculosis antibody
presence (i.e., Optical Density (O.D.) obtained by means
of ELISA) as a canonical response
MANOVA Pillai? s trace F-value P-value
Early captivity (t0 vs t1) 0.974 15.793 0.001
Long-term captivity (t0 vs t1-t5) 0.818 10.284 3.468e-08
Treatment (t2 vs t3) 0.735 1.979 0.141
ANOVA Mean ? SE (Min-Max) F-value P-value
Early captivity
IgG (O.D.) 37.993 6.352e-06
t0 0.22 ? 0.02 (0.16-0.4)
t1 0.5 ? 0.04 (0.22-0.7)
Leukocytes (?10 3 cells/μl) 5.338 0.032
t0 11.2 ? 1.33 (5.56-21.98)
t1 15.16 ? 0.86 (12.11-19.95)
Platelets (?10 3 cells/μl) 6.652 0.018
t0 260.82 ? 52.41 (46 ? 563)
t1 470.55 ? 58.3 (109 ? 784)
Monocytes (?10 3 cells/μl) 7.370 0.014
t0 2.16 ? 0.58 (0.6-6.2)
t1 0.59 ? 0.15 (0.2-2)
Eosinphils (?10 3 cells/μl) 5.085 0.036
t0 3.13 ? 0.67 (1 ? 8.4)
t1 5.08 ? 0.72 (1.8-10)
Basophils (?10 3 cells/μl) 10.604 0.004
t0 1.76 ? 0.37 (0.6-5.2)
t1 0.59 ? 0.05 (0.4-1)
Total Protein (g/dl) 15.952 0.001
t0 7.1 ? 0.13 (6.4-7.9)
t1 8.31 ? 0.27 (7 ? 9.6)
Long-term captivity
IgG (O.D.) 10.432 0.002
t0 0.23 ? 0.03 (0.17-0.4)
t1-t5 0.48 ? 0.03 (0.196-1.37)
Basophils (?10 3 cells/μl) 56.797 1.644e-09
t0 1.38 ? 0.13 (0.6-1.7)
t1-t5 0.61 ? 0.04 (0.2-1.2)
Treatment
Haemoglobin (g/dl) 4.689 0.041
t2 10.46 ? 0.46 (7.7-13.2)
t3 11.92 ? 0.49 (8.6-13.6)
PCV (%) 5.061 0.034
t2 33.25 ? 1.54 (24.5-42.7)
t3 38.33 ? 1.65 (27.4-44.8)
ANOVA values illustrate statistically significant parameters associated with
captivity and treatment effect.
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normality of lymph node size and swelling, may not be
sensitive enough to detect animals with low grade le-
sions. The necropsied ibexes had abscesses, most fre-
quently, in the lymph nodes of the anterior body part,
which agrees with previous reports [4,10,39,41]. How-
ever, these studies did not observe a high percentage of
visceral lesions (66.7% in our study). Thus, improved
methods for clinical assessment are needed. On the other
hand, the ELISA also classified as negative an important
percentage of clinically affected ibexes. Since CLA is a
chronic condition, the ibexes in the initial phase of infec-
tion may not have had time to develop a detectable anti-
body response. This may have occurred in at least the
three ibexes displaying more severe affectations and sero-
converting later. However, false negative results derived
from inadequate sensitivity cannot be discarded. The
ELISA used was described as highly sensitive (98%) and
specific (100%) in CLA-affected lambs [31]. These values
were lower in our study. However, despite unknown sen-
sitivity and specificity, ELISA is considered a suitable op-
tion for the detection of C. pseudotuberculosis infection
in Iberian ibexes.
The lack of correlation between treatment and the
humoural response contrasts with the increase in
antibody levels observed in domestic small ruminants
immunized with bacterin vaccines [42], toxoid-based
vaccines [43] or combined vaccines [18]. Immunity
against C. pseudotuberculosis is described as complex,
involving both cellular and humoural immune responses.
In the last several years, IFN-γ and cytotoxic T-cells
have been described as the main factors responsible
Figure 3 Box plots showing significant differences (p < 0.05) in the mean leukocyte (WBC), monocyte, basophil, eosinophil and platelet
counts, and in the serum total protein (TP) concentration of the ibexes at the moment of capture in the wild (t0) and at the first
handling within the enclosure (t1).
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Therefore, the absence of an antibody response to vac-
cination may not be interpreted as a lack of vaccine
effect. Aqueous adjuvants have been shown to diminish
vaccine efficacy [45]. We cannot separate the effects of
vaccines and those of antibiotics, as all the ibexes re-
ceived both treatments and there was no control group.
This was unavoidable as this was not a designed experi-
ment, but a management intervention. However, the
treated ibexes displayed significant health improvement
at handlings t4 and t5, preceded by six months without
any treatment. An antibiotic-only treatment is not ex-
pected to have such a long lasting effect, which indi-
cates a vaccine effect. The lack of seroconversion in
three ibexes suggests individual differences in immuneresponse. However, a lack of sensitivity of the ELISA
test used could also explain this. The possibility of
cross-reactions with M. bovis and M. a. paratubercu-
losis [3,46] was discarded with specific ELISAs. Previ-
ous studies have not found tuberculosis in Iberian ibexes
from our study area [47,48]. Thus, the M. bovis ELISA
positive ibex in this study is probably a false positive as
other samples of the same ibex collected later displayed a
negative result.
Apart from higher basophil and eosinophil cell counts,
the mean haematological parameters of the ibexes in-
cluded in our study were similar to the reference values
previously described [49,50]. Basophils apparently de-
creased once in captivity but the factors determining the
observed decrease are unclear. In fact, controversy
Figure 4 Box plots showing the significant differences (p < 0.05)
in the mean haemoglobin concentration and in the PCV of the
ibexes just before the start of treatment (t2) and one month
later (t3).
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and this is a difficult-to-assess parameter in veterinary
clinical pathology. Since it is a minority blood cell type,
small differences in count may be observed as large vari-
ations. Hence, the observed differences could be due to
differences in the capture and analytical methods. The
increase of WBC and eosinophil cell counts could be
related to both CLA (bacterial-induced leukocytosis) and
higher parasite load derived from captivity conditions
(parasite-induced eosinophilia). Parasite-induced eosino-
philia is a well-known phenomenon [51,52]. Previous
studies reported high prevalences and intensity of para-
sitosis by ixodides and helminthofauna in NGR Ports
of Tortosa Beseit [53]. Coprology did not reflect a
marked increase in parasitic load. Conversely, high tick
loads were observed during handlings. Increased serum
total protein concentration may reflect increased serum
immunoglobulins (antibodies anti-C. pseudotuberculosis)
and platelet counts may increase as a result of wounds
caused by extremely high tick loads. Monocyte cell counts
were also higher with regard to values previously pub-
lished [49], which could be associated with stress in-
duced by the box-trap capture method or to subclinical
inflammatory conditions [54]. Although the leukogram is
considered a useful tool for monitoring infectious pro-
cesses, ruminants may show no or few changes even
during severe infections [55]. Haemoglobin concentration
and PCV increased from t2 to t3. This could be ex-
plained by an increased stress response due to proximity
between t2 and t3 handlings, sensitization and increased
catecholamine release in t3 [56]. However, it could alsobe due to the start of treatment in t2 and improved
health of ibexes in t3.
The acute phase reaction is a physiological response to
infection, inflammation, injuries or stress and includes
the increase or decrease in the expression of a protein
family called APP. Hence, the quantification of APP can
be a way to determine the health status of an animal or
a herd [57] and thus be used to assess disease pathogen-
esis, the evolution of an infection or the efficacy of drugs
and vaccines. For example, CLA-affected sheep have
been described to display higher serum concentrations
of Hp, SAA and AGP [55,58]. Although the validation of
analytical methods and reference values of SAA and Hp
in Iberian ibex have been provided recently [33], we
were not able to detect significant changes in Hp, SAA
nor ASG. Hp and SAA have been proposed as major
acute phase proteins in CLA-affected sheep and ASG is
considered a moderate acute phase protein in chronic
stages [58]. Although interspecific differences may exist,
the frequency of sampling was lower in our study and
changes in the APP concentration may have gone un-
noticed due to the spaced sampling.
Conclusion
This is the first outbreak of CLA in Iberian ibex de-
scribed in the literature, displaying high morbidity and
mortality. However, captivity conditions had an im-
portant role over the course of the disease. This makes
clear the need for improved methods for early detec-
tion of infected animals and quarantine protocols. The
CLA-ELISA test used in the present study can be a
useful tool for decision-making during quarantine man-
agement. However, sensitivity and specificity should be
further assessed.
Treatment consisting of both vaccination and anti-
biotic therapy seemed to prevent mortality and alleviate
disease severity, although this was not reflected by the
humoural response. An experimental design aimed at
differentiating the effect of vaccine from that of antibiotics
was not possible in the present study. Despite the fact
that time lapses between consecutive handlings (and
treatments) point to a vaccine effect, an experimental
design would be desirable if future studies are launched
to assess vaccine efficacy.
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